Mixed endometrial carcinoma refers to a tumor that comprises 2 or more distinct histotypes. We studied 18 mixed-type endometrial carcinomas-11 mixed serous and low-grade endometrioid carcinomas (SC/EC), 5 mixed clear cell and low-grade ECs (CCC/EC), and 2 mixed CCC and SCs (CCC/SC), using targeted next-generation sequencing and immunohistochemistry to compare the molecular profiles of the different histotypes present in each case. In 16 of 18 cases there was molecular evidence that both components shared a clonal origin. Eight cases (6 EC/SC, 1 EC/CCC, and 1 SC/CCC) showed an SC molecular profile that was the same in both components. Five cases (3 CCC/ EC and 2 SC/EC) showed a shared endometrioid molecular profile and identical mismatch-repair protein deficiency in both components. A single SC/EC case harbored the same POLE exonuclease domain mutation in both components. One SC/CCC and 1 EC/CCC case showed both shared and unique molecular features in the 2 histotype components, suggesting early molecular divergence from a common clonal origin. In 2 cases, there were no shared molecular features, and these appear to be biologically unrelated synchronous tumors. Overall, these results show that the different histologic components in mixed endometrial carcinomas typically share the same molecular aberrations. Mixed endometrial carcinomas most commonly occur through morphologic mimicry, whereby tumors with serous-type molecular profile show morphologic features of EC or CCC, or through underlying deficiency in DNA nucleotide repair, with resulting rapid accrual of mutations and intratumoral phenotypic heterogeneity. Less com-monly, mixed endometrial carcinomas are the result of early molecular divergence from a common progenitor clone or are synchronous biologically unrelated tumors (collision tumors).
M ixed endometrial carcinomas contain 2 or more distinct histotypes of endometrial carcinoma, with at least 1 histotype being a type II endometrial carcinoma. 1 Each component histotype by definition has to represent >5% of the tumor, on the basis of the finding that the presence of as little as 5% of a more aggressive histotype can be associated with more aggressive clinical behavior. 2 Although the frequency of mixed carcinoma diagnosis likely varies between institutions depending on the diagnostic threshold used, mixed carcinomas can constitute 5% or more of endometrial cancer diagnoses. [3] [4] [5] Excluding mixed EC and undifferentiated carcinoma (also referred to as dedifferentiated carcinoma), the most common scenario for mixed endometrial carcinoma based on the literature is mixed EC and serous carcinoma (SC), followed by mixed EC and CCC. [2] [3] [4] [5] [6] The diagnosis of mixed carcinoma as currently defined relies predominantly on histologic features, as the distinctive components present should display classic or well-accepted variant morphologic appearance of the respective histotypes. Immunohistochemistry may be used to support the presence of mixed components, and a combination of p53 and p16 may be used to differentiate between EC and SC, as most SCs show aberrant p53 immunostaining (diffuse nuclear staining or complete absence of nuclear staining of the tumor cells) and diffuse p16 immunostaining. [7] [8] [9] [10] To distinguish between EC and CCC, markers such as HNF-1b, napsin A, and estrogen receptor may be useful given that great majority of CCCs show an HNF-1b-positive and napsin Apositive immunoprofile, although the same immunoprofile can be seen in a subset of SC as well. [11] [12] [13] [14] [15] In recent decades, there is increasing appreciation of the extent of morphologic overlap between the different histotypes of endometrial carcinoma. 16, 17 For instance, some endometrioid carcinomas (ECs) can focally display clear cell changes that mimic the solid or papillary patterns of CCC, 18 and some SCs may display a predominantly glandular morphology that mimics EC. 19 This realization raises a fundamental question about the oncogenesis of mixed carcinoma-more specifically, do the different histotypes in mixed carcinoma arise through completely unrelated oncogenic mechanisms (collision tumor) or do they share a common oncogenic origin, that is, either progression from one histotype to another histotype, divergence from a common progenitor into different histotypes, or a single tumor histotype that focally displays a variant morphology that mimics a different histotype.
To gain further biological insights into mixed endometrial carcinomas, we performed a comprehensive mutation screen and immunohistochemical analyses on 18 mixed endometrial carcinomas with spatially distinct histotype components. Our results show that the different histotype components in most mixed tumors are clonally related and share the same molecular alterations.
METHODS

Study Samples
This study included 18 mixed endometrial carcinomas that were identified from the pathology archives at Vancouver General Hospital (Vancouver, Canada) and Calgary Laboratory Services (Calgary, Canada). All the cases were reviewed by 2 study pathologists (M.K. and C.-H.L.) and fulfilled the following inclusion criteria. First, all mixed endometrial carcinomas were from hysterectomy specimens and contained 2 different histologic types of endometrial carcinoma, with at least 1 being a type II carcinoma, as defined by World Health Organization 2014. 1 Second, the different histotypes displayed classic or well-recognized variant histologic features and formed spatially distinct areas that are not intimately admixed, such that the tissue from the different histotype components can be cored separately (0.6 mm tissue cores). The diagnoses in these cases were made on the basis of morphologic findings only. We excluded cases that were difficult to histotype because of the presence of ambiguous histologic features throughout the tumor (without spatially distinct areas of different histologic histotypes). 20 The study was approved by the Institutional Review Board.
Immunohistochemistry and Interpretation
All immunohistochemical analyses were performed on representative whole-tissue sections from hysterectomy specimens. For HNF-1b, napsin A, p53, and mismatch-repair proteins (MMR) (MLH1, MSH2, MSH6, and PMS2), the primary antibodies used and the staining methods are the same as that reported previously. 12, 14, 21, 22 The mouse monoclonal p53, clone DO-7 (catalog number: M7001) antibody was obtained from Dako (Burlington, ON, Canada), the rabbit polyclonal HNF-1b (catalog HPA002083) antibody was obtained from Sigma (St Louis, MO), and the rabbit polyclonal napsin A (catalog 352 A) antibody was obtained from Cell Marque (Rocklin, CA). For MMR proteins, slides were incubated with MLH1 (mouse monoclonal antibody, 1:50 dilution, cat#:NCL-L-MLH1, clone ID:ES05; Leica Microsystems, Newcastle, UK), MSH2 (mouse monoclonal antibody, 1:1000 dilution, cat#286 M-16, clone ID:G219-1129; Cell Marque), MSH6 (rabbit monoclonal antibody, 1:200 dilution, cat#:CLAC-0047, clone ID:EP49; Cedarlane Corporation, Burlington, ON, Canada), and PMS2 (rabbit monoclonal antibody, 1:20 dilution, cat#:CLAC-0049, clone ID:EP51; Cedarlane Corporation) and processed using the Leica Bond Max platform (Leica Microsystems, Wetzlar, Germany) as per manufacturer's protocol with proprietary reagents. The detection system used was the Bond polymer refine.
Napsin A cytoplasmic staining was quantified on the basis of percentage tumor cell staining, and tumors showing Z5% staining was considered positive. HNF-1b immunostain was considered to be positive if the tumor exhibited at least moderate nuclear staining intensity in >70% of tumor cells. 12 P53 immunostain was considered to be aberrant (mutated/inactivated) if the tumor exhibited (1) diffuse moderate to strong uniform nuclear staining in Z70% of the tumor cells (diffuse), or (2) complete absence of nuclear staining in the tumor cells in the presence of focal nuclear staining of the stromal cells (complete absent). Immunostain for p53 was considered normal (wild-type pattern) if any degree of nondiffuse nuclear staining (< 70%) of the tumor cells was present. 23 For MLH1, MSH2, MSH6, and PMS2, staining is considered abnormal/absent when there is loss of nuclear expression by the tumor cells compared with internal positive control (stromal fibroblasts and inflammatory cells).
DNA Extraction
For each case, tissue cores (0.6 mm diameter) of different histologic components and of the corresponding normal tissues were obtained from formalin-fixed paraffin-embedded (FFPE) blocks. The tumor cores were derived from the most superficial aspect of the tumor (adjacent to the endometrial cavity), and they contained only histologically viable tumor with minimal inflammatory infiltrates. To ensure that each tissue core contained only the histologic component that it was supposed to represent, an individual tumor FFPE block was flipped over and re-embedded to produce a hematoxylin and eosin slide from the opposite side of the block, and tissue cores that were contaminated by a different histologic type were excluded from further analysis. Normal tissue that was distant from and uninvolved by endometrial carcinoma was used for comparison, and the examples of the corresponding normal tissue examined included cervix, fallopian tube, and ovary. DNA was extracted from the tissue cores using the Qiagen FFPE DNA extraction kit based on manufacturer's protocols.
Targeted Gene Panel Sequencing Analysis and Validations
mutated in endometrial carcinomas. [24] [25] [26] [27] [28] [29] These included ABCC9, ARID1A, ARID5B, CCND1, CHD4, CSMD3, CTCF, CTNNB1, EP300, FBXW7, GRLF1, FGFR2, KRAS, MAP3K4, PIK3CA, PIK3R1, PIK3R2, POLE, PPP2R1A, PTEN, RBMX, RPL22, SPOP, TP53, TSPYL2, and ZFHX3, similar to that described previously. 14 The Illumina custom TruSeq amplicon panel was designed using Illumina's DesignStudio and included 1440 amplicons (175 bp) that covers 98% of the exons and untranslated regions of these 26 genes. Custom amplicon libraries were prepared starting with 250 ng of FFPE DNA as per Ilumina's Custom TruSeq Library Preparation protocol. Before pooling, normalization was performed by quantifying individual libraries using the Qubit fluorometer, then pooled on the basis of equal concentrations. Library pools were then quantitated for amplifiable libraries using the Kapa Biosystems FAST qPCR SYBR quantification kit based on manufacturer's protocols. Pooled TruSeq libraries were sequenced using the Illlumina MiSeq using 300 cycle V2 kits. Analysis was performed using the Miseq Reporter and somatic variant caller 3.2.3.0. Only somatic nonsynonymous mutations passing quality filter with at least 10% variant allele frequency were further evaluated. These mutations were manually checked in bam files using Integrated Genome Viewer and validated orthogonally by direct Sanger sequencing using primer sets that target the regions containing the mutations. Mutations that were common between the different histologic components were further confirmed to be somatic in nature by analyzing DNA derived from corresponding normal tissue.
RESULTS
Clinical and Pathologic Features of the Mixed Endometrial Carcinoma
Eighteen mixed endometrial carcinomas were studied, and these included 11 mixed EC and SC, 5 mixed EC and CCC, and 2 mixed SC and CCC tumors. The clinical and pathologic features of these 18 cases are summarized in Table 1 . All patients were postmenopausal in status. The mean age was 69 years for the patients with mixed EC and SC, 69 year for patients with mixed EC and CCC, and 67 years for patients with mixed SC and CCC. Clinical follow-up information was available for 16 of the 18 patients (Table 1 ), and 7 patients had limited follow-up with a follow-up period of <2 years.
For mixed carcinomas with EC and SC, the proportion of SC component ranged from 35% to 90% of the tumors (average of 70%). All cases showed direct contact between the 2 components, except 1 (case 11) in which the apparent EC and SC components involved different parts of an endometrial polyp. The EC component demonstrated prototypical endometrioid histology with predominantly glandular or villoglandular architecture, and all were low-grade (FIGO grade 1 or grade 2) tumors that displayed low-grade nuclear features (lacking nuclear pleomorphism) ( Fig. 1 ). None of the EC components exhibited definitive squamous differentiation, although 3 showed squamoid areas, and 1 showed mucinous differentiation. Mitotic rates in the EC components were variable between cases, ranging from 1 to 25/ 10 high-power fields (HPF) (1.5 mm 2 ). The SC component demonstrated prototypical serous histology with predominantly papillary architecture, prominent papillary/luminal surface tumor cell budding, and cellular detachment ( Fig. 1 ). There was high-grade nuclear atypia present in all cases, and 3 cases showed prominent nuclear pleomorphism (> 3:1 variation in nuclear size) with tumor giant cells. Mitotic figures were readily identified, ranging from 14 to 48/10 HPF.
For mixed carcinomas with EC and CCC, the proportion of CCC component ranged from 10% to 85% (average of 47%). The EC components were low grade (FIGO grade 1 or 2) in all cases and demonstrated typical endometrioid histologic features (Figs. 2A-D). Squamous Stromal hyalinization was prominent, and the mitotic rate (6 MF/10 HPF) was lower than the corresponding SC component. In case 18, the SC component showed papillary architecture with high-grade nuclei and surface tumor budding (Fig. 2H ). The CCC component showed a mix of tubulocystic and glandular architecture with hobnail cells that featured clear to eosinophilic cytoplasm ( Fig. 2G ). Mitotic rates were comparable between the SC (15 MF/10 HPF) and CCC (13 MF/10 HPF) components.
Immunohistochemical and Genetic Features of Mixed EC and SC
We performed targeted whole-exon sequencing of selected genes that have been shown to be recurrently mutated in endometrial cancers (including endometrioid, serous, and clear cell histotypes), using DNA extracted from the different histologic components of mixed endometrial carcinoma. The coding regions of 26 endometrial cancer genes (except for exon 1 of ARID1A, which was not covered because of primer design constraint) were sequenced using a custom-designed amplicon-based targeted sequencing panel. Of the 36 tumor samples (18 pairs), there was an average of 821-fold coverage per amplicon (range 430-to 2070-fold), and 94% of the amplicons had a median coverage in the 36 tumor samples of at least 50-fold. We also performed p53 and MMR protein immunohistochemistry on these cases and scored the staining results of the different histologic components separately. Of the 11 mixed carcinomas with SC and EC, we identified somatic mutations in 9 cases ( Table 2 ). The mutations were either identical or partially shared between the SC and EC components in 7 of 9 cases. Of the 7 cases with identical or partially shared mutations, 3 MMR-intact tumors (case 2, 3, and 7) harbored prototypical serous-type mutations with concurrent somatic TP53 and PPP2R1A (hotspot) mutations with notable absence of PTEN, ARID1A, CTNNB1, or KRAS mutations in both the histologically apparent EC and SC components, whereas 1 MMR-intact tumor (case 1) showed the same missense somatic TP53 mutations in both components. This was further confirmed by p53 immunohistochemistry that demonstrated aberrant p53 staining in the corresponding EC and SC components in these cases (Figs. 3A-D). Two other tumors (case 4 and 8) showed the same somatic mutations in ARID1A, PTEN, and RPL22 between the corresponding EC and SC components. Both tumors showed wild-type p53 staining and were MMR-deficient with the same pattern of MMR protein loss in the corresponding EC and SC components (case 4 and 8). The remaining case (case 9) with partially shared mutations between the EC and SC components harbored POLE exonuclease domain mutation (L424V) and showed isolated MSH6 loss in both components (Figs. 1E, F, 3E, F). This tumor possessed a large number of point mutations, with some mutations being shared by both EC and SC components and other mutations that were unique to either the EC or SC component only ( Table 2 ). Immunohistochemistry for p53 showed wild-type staining in both EC and SC components.
Among the 9 mixed EC and SC with demonstrable mutations, 2 cases (case 10 and 11) showed completely different mutations between the corresponding EC and SC components. The EC component in both cases harbored prototypical endometrioid-type mutations (PTEN and ARID1A mutations), whereas the SC component harbored prototypical serous-type mutations (TP53, PPP2R1A, and/or FBXW7). The corresponding EC and SC components also displayed discordant p53 immunostaining patterns with aberrant diffuse nuclear staining in the SC component and wild-type staining in the EC component ( Figs. 1G, H, 3G , H). Case 10 showed intact MMR protein expression in both components, whereas case 11 showed intact MMR protein expression in the SC component but concurrent MLH1 and PMS2 loss in the EC component. Case 11 was the only mixed EC and SC case in which the components were not in direct contact with each other.
There were 2 mixed EC and SC cases (case 5 and 6) in which no mutations were demonstrated in either the EC or SC component. These tumors showed intact MMR protein expression and the same aberrant p53 staining pattern (diffuse staining in case 5 and complete loss of staining in case 6) in the corresponding EC and SC components. The similar alteration in p53 and the concordant lack of demonstrable mutations observed in the corresponding EC and SC component suggests molecular commonality.
Immunohistochemical and Genetic Features of Mixed EC and CCC
Among the 5 mixed endometrial carcinomas with EC and CCC components, 4 were MMR-deficient tumors in which the same pattern of MMR protein loss was found in the corresponding EC and CCC components ( Fig. 4 ). All 4 tumors showed wild-type p53 expression, and the CCC components were all positive for HNF-1b and napsin A, whereas the EC components were all negative for these markers (Figs. 4A, B) . Genetically, the EC and CCC components in 3 of the 4 MMR-deficient tumors showed shared somatic mutations involving genes such as PTEN, ARID1A, and RPL22, indicating a common genetic origin (Table 3 ). In case 15, both the EC and TP53 frameshift mutation and a loss of tumoral p53 expression in both the endometrioid component (napsin A/ HNF-1b-negative) and the clear cell component (napsin A/HNF-1b-positive). There were no additional molecular abnormalities demonstrated in either component. We interpreted this as a serous-type endometrial carcinoma with endometrioid-like morphology and clear cell-like morphology in different areas of the tumor.
Immunohistochemical and Genetic Features of Mixed SC and CCC
There were 2 mixed endometrial carcinomas with SC and CCC in our series, and both showed intact MMR protein expression ( Fig. 3) . The CCC component in case 17 was positive for HNF-1b and napsin A, whereas the SC component was negative for these markers (Figs. 5A, B ). Our mutation screen showed 2 somatic point mutations in PIK3CA, with N345I (C2 domain of PIK3CA) present in both the SC and CCC components and M1004I (exon 20 PIK3CA mutation) found only in the SC component. Furthermore, the SC component showed aberrant p53 staining, whereas the CCC component showed wild-type p53 staining (Figs. 5C, D) . Histologically, the SC component was focally confined to an endometrial polyp, whereas the CCC component involved the same endometrial polyp as well as the background endometrium. There was no direct contact between the 2 components in the histologic sections sampled. Despite the shared genetic commonality (PIK3CA N345I), the observed immunoprofile suggests early divergence in the tumorigenic development that resulted in synchronous SC and CCC. In case 18, the CCC component was positive for napsin A and negative for HNF-1b, whereas the SC component was negative for both markers (Figs. 5E, F) . The SC and CCC components harbored identical somatic TP53, PPP2R1A, and PIK3CA mutations, and both showed aberrant (strong nuclear) p53 staining (Figs. 5G, H) . These molecular findings suggest that the histologically apparent SC and CCC components in this case represent a single tumor type.
DISCUSSION
Mixed endometrial carcinomas constitute a small subset of endometrial carcinomas, but they present a 
p53 (mutated/ diffuse), MMR (intact), HNF1B (negative), Napsin A (positive) significant diagnostic challenge. In this study, we molecularly characterized the individual histotype components in 18 mixed endometrial carcinomas and found that the histologically distinct components in most of the mixed endometrial carcinomas shared the same molecular alterations. The Cancer Genome Atlas (TCGA) studies recently proposed a molecular classification scheme for endometrial carcinomas on the basis of comprehensive genetic, epigenetic, and proteomic analyses of a large series of cases. 24 This proposed molecular classification approach has been further validated with respect to its clinical significance. [30] [31] [32] The recognition of the different molecular subtypes of endometrial carcinomas gives us a general framework to interpret our findings here. Using the molecular classification scheme proposed by TCGA and using MMR protein immunohistochemistry as a surrogate marker for high microsatellite instability (MSI-H), 24, 33 our results showed that mixed endometrial carcinomas can be separated into 4 different molecular categories- (1) 
Serous Molecular Type With Areas Resembling Other Endometrial Histotype
On the basis of TCGA finding, the serous/serouslike molecular type of endometrial carcinoma harbored frequent TP53 mutations with PPP2R1A and/or FBXW7 mutations occurring in a smaller subset, and lacked evidence of MSI-H and POLE exonuclease domain mutations. There were 8 cases (case 1, 2, 3, 5, 6, 7, 16, and 18) that showed identical serous-type molecular abnormalities between the corresponding histologic components (concurrent TP53 and PPP2R1A mutations, or TP53 abnormality only without other demonstrable molecular abnormalities). These included 6 histologically mixed EC/ SCs, 1 histologically mixed EC/CCC, and 1 histologically mixed SC/CCC. In the mixed EC/SC scenario, it is increasingly recognized that a subset of SC can exhibit tubuloglandular architecture that histologically mimics EC. 19, 20 Similar to tubo-ovarian high-grade SC, endometrial SCs also harbor TP53 mutations and show a high degree of somatic copy number alterations, 24 which reflect chromosomal instability. However, these somatic copy number alterations may not be homogenous across the tumor as demonstrated by intratumoral heterogeneity of DNA ploidy, a surrogate for copy number alterations. 34 Consequently, nuclear grade may also vary.
Case 16 (EC/CCC) and case 18 (SC/CCC) exhibited identical serous-type molecular profiles in both components with compelling morphologic and immunohistochemical evidence for the clear cell component (Napsin A-positive) and the endometrioid or serous component (HNF-1b/ napsin A-negative). We have previously observed that a subset of TP53-mutated pure endometrial CCCs harbor prototypical serous-type mutation profiles (with concurrent TP53 and PPP2R1A mutations, in the absence of ARID1A or PTEN mutations). 14 These 8 mixed-type cases are all serous moleculartype endometrial carcinomas that morphologically mimic other histotypes (low-grade EC or CCC). Our findings are in line with the TCGA data whereby the majority of mixed tumors clustered in the copy number high cluster 4 and are serous-like with respect to their molecular type. 24 Immunohistochemical analysis of p53 expression can aid in the recognition in these cases of morphologic mimicry. If p53 immunostaining results suggest TP53 mutation (diffuse strong tumor nuclear staining or a complete absence of tumor nuclear staining in the presence of appropriate internal stromal positive control) in both apparent histologic components, the most likely diagnosis is SC (with endometrioid-like area and/or clear cell-like area), as these tumors show serous-like molecular profiles. However, we do acknowledge that accurate classification of tumors with pure clear cell morphology, abnormal TP53, and expression of napsin A/HNF-1b requires further study and ideally a greater insight into the defining molecular features of endometrial CCC.
Hypermutated/Ultramutated Molecular Type With MMR Deficiency/POLE Mutation
There were 5 tumors (cases 4, 8, 12, 13, and 14) that exhibited an identical pattern of MMR deficiency and 1 tumor (case 9) that harbored identical POLE exonuclease domain mutation between the corresponding histologic components. The mutation profiles in these cases were endometrioid in type. Case 9 was a POLE-ultramutated endometrial carcinoma (case 9) with a POLE exonuclease domain mutation (L424V) and a loss of MSH6 expression that was present in both the endometrioid and the serous components. This POLE exonuclease domain mutation was previously documented to be present in endometrial carcinoma with an ultramutated genomic landscape, and a subset of POLE-mutated tumors can also be MSI-H. 24 A large number of somatic mutations (point mutations and small insertions/deletions) were identified in this case, some of which were common but some were different between the corresponding endometrioid and serous components. The 5 MMR-deficient tumors as a group also harbored a high number of somatic mutations, 24 and 2 (cases 4 and 8) showed mixed endometrioid and serous histologic components. In these 3 mixed EC/SC cases with DNA nucleotide repair deficiency (MMR deficiency and/ or POLE exonuclease domain mutation), the serous-like component exhibited prototypical histologic features of SC, with at least focally high-grade nuclear features, significant mitotic activity (>10 MF/10 HPF), prominent nuclear stratification/tumor budding, and papillary architectural features. In contrast, the corresponding endometrioid component showed typical endometrioid features with villoglandular or glandular architecture, smooth luminal border, and low nuclear grade. Although it is unclear whether the presence of a serous-like area in these molecular contexts portends any clinical significance, it is worth noting that the serous-like area in our 3 cases lacked evidence of TP53 mutation (a disease-defining event in SC) by sequencing and immunohistochemistry. Therefore, it is more likely that the presence of such serous-like areas reflects the tendency for POLE-ultramutated EC and MMR-deficient EC to display serous-like features, as observed previously. 35 It is important to note that POLEultramutated tumors have an excellent prognosis when managed by conventional treatment algorithms and that MMR-deficient (MSI-H) tumors have a better prognosis than serous-type endometrial carcinoma. 24, 31, 32 We therefore believe based on current evidence that it is important not to mistaken these tumors as SC or mixed carcinoma with serous component because of their better prognosis compared with typical TP53-mutated pure SC. 6 Three (cases 12, 13, and 14) of the 4 mixed EC/CCCs were MMR deficient and displayed the same pattern of MMR deficiency between the corresponding endometrioid and clear cell components. It is important to note that the clear cell components in cases 12, 13, and 14 all showed prototypical clear cell immunoprofile (napsin A and HNF-1b-positive), whereas the corresponding endometrioid components were all immuno-negative for napsin A and HNF-1b. 12, 15 Overall, our findings here show a high frequency of MMR deficiency in mixed EC and CCC tumors (75%). Given that MMR deficiency is rare in pure endometrial CCC, 14, 36, 37 it appears likely that these MMR-deficient mixed EC and CCC tumors are biologically different from pure endometrial CCC. It is, however, unclear whether these MMR-deficient (MSI-H) tumors with mixed endometrioid and clear cell morphology would behave clinically more like MMR-deficient (MSI-H) tumors with pure endometrioid histology or MMR-intact pure endometrial CCC, particularly in terms of therapeutic response. Future studies are needed to address these issues.
Tumor Showing Early Molecular Divergence From Common Progenitor
One of the 2 mixed SC/CCC cases (case 17) showed intact MMR expression and wild-type POLE exonuclease domain in both the clear cell component (napsin A/HNF-1b-positive) and the serous component (napsin A/HNF-1bnegative). The serous component also harbored an exon 20 PIK3CA mutation (M1004I) that was not identified in the clear cell component. Although these findings would suggest that these are 2 unrelated and distinct tumorssynchronous SC and CCC-they do share in common a somatic activating mutation involving the C2 domain of PIK3CA. 38, 39 Histologically, both the serous component and the clear cell component involved an endometrial polyp (with serous component being confined to the polyp), with no direct contact between the 2 components. It is plausible that the serous and the clear cell components share the same precursor progenitor cells in the endometrial polyp that harbored this PIK3CA (N345I) mutation, with the serous component going on to acquire a further mutation in exon 20 of PIK3CA and alterations involving TP53, and with the clear cell component presumably going on to acquire other molecular abnormalities. We therefore interpret this case as an example of early molecular divergence from a common progenitor clone.
In case 15 (mixed EC/CCC), there were several mutations identified in each histologic component, but none was shared by both components. Both components demonstrated the same pattern of MMR deficiency (MSH6 loss only), and both were negative for napsin A and HNF-1b by immunohistochemistry. On the basis of these findings, the most probable explanation is that there is likely a germline MSH6 mutation (Lynch syndrome) that led to the development of 2 synchronous MSH6deficient ECs (1 showing endometrioid morphology and 1 showing clear cell morphology). This is, however, speculative in nature as we do not know whether this patient has Lynch syndrome. More importantly, it is also unclear whether MMR-deficient (MSI-H) pure CCC behaves similarly as MMR-intact pure endometrial CCC in the endometrium. Therefore, one may also consider placing case 15 in category 2 (hypermutated molecular type) if the presence of either focal or diffuse clear cell features in an MMR-deficient setting is clinically and therapeutically different from typical MMR-intact CCCs.
Collision Tumors
There were 2 cases in our series (cases 10 and 11) that showed different molecular alterations in the different histologic components with no overlap at all, and both were mixed EC/SC in histology. These appear to represent biologically unrelated tumors that have occurred synchronously in the endometrium (collision tumor). The endometrioid component in these 2 cases harbored endometrioid-type mutations (PTEN and/or ARID1A) and displayed a wild-type p53 immunostaining pattern, whereas the corresponding serous component harbored serous-type mutations (TP53 and/or PPP2R1A) and displayed a mutated p53 immunostaining pattern. Furthermore, the EC component in case 11 was MMR deficient, whereas the corresponding SC component showed intact MMR protein expression. These findings demonstrate that the corresponding endometrioid and serous components in these 2 cases are molecularly distinct. It is important to note that we did not identify any cases in our series that may have progressed from low-grade EC to SC. Coenegrachts et al 40 recently studied a series of mixed endometrial EC/SC and found that the individual histologic components shared the sample mutations in 30% of the cases but displayed different mutations in 35% of cases. This is in keeping with our findings that some of the mixed EC/SC shared molecular commonalities (ie, SCs with areas that resemble EC or hypermutated/ultramutated molecular subtype), whereas some mixed EC/SCs appear to represent true collision tumors.
Proposed Diagnostic Approach to Suspected Mixed Endometrial Carcinoma
With the molecular insights gained here, we would like to recommend the use of p53 and MMR immunohistochemistry and POLE exonuclease domain sequencing (by Sanger or next-generation sequencing) on all suspected cases of mixed endometrial carcinoma. If there is identical MMR deficiency and/or POLE exonuclease mutation present in the different histologic components, the case should be diagnosed as an EC with MMR deficiency and/or POLE exonuclease domain mutation and be further qualified that it exhibits mixed serous or clear cell features (to facilitate communication to pathology colleagues). If MMR deficiency and/or POLE exonuclease domain mutation is only observed in 1 of the histologic components, this would provide support for a mixed-type carcinoma (either as true collision tumor or as molecular divergence from common progenitor clone). One would subsequently rely on p53 immunohistochemistry to determine what the remaining histologic component may be. For instance, case 11 showed MMR deficiency and wild-type p53 immunostaining in the histologically endometrioid component and intact MMR proteins but mutated p53 immunostaining in the histologically serous component. It was therefore a synchronous MMR-deficient EC and MMR-intact SC (collision tumor). If the different histologic components show both intact MMR expression and wild-type POLE exonuclease domain, one would need to evaluate p53 immunostaining in each of the histologic components. On the basis of our findings here, it is likely that a majority of these cases will turn out to display the same mutated p53 staining pattern in the different histologic components, indicating that these are serous-type endometrial carcinomas with areas that mimic other endometrial histotypes. Although this proposed diagnostic approach utilizes immunomarkers (p53 and MMR proteins) that are available in most pathology laboratories, sequencing for POLE exonuclease domain mutation is not available in most laboratories at the present. We, however, anticipate that it will become more widely available as an ancillary molecular test, given the strong prognostic significance of POLE exonuclease domain mutation in endometrial carcinoma, particularly among tumors with high-grade histologic features. 24, 31, 32, 41 In summary, our studies on mixed endometrial carcinomas show that most mixed endometrial carcinomas diagnosed on the basis of morphologic features represent a single tumor type that demonstrates varied histologic appearances (morphologic mimicry/intratumoral phenotypic heterogeneity). Tumors with DNA repair defects, with resulting intratumoral heterogeneity, are the second largest group. We, however, also confirmed that true mixed endometrial carcinomas that are composed of genetically distinct synchronously occurring endometrial carcinoma histotypes do occur, albeit rarely. These results suggest that the integration of selected ancillary studies such as p53 and MMR protein immunohistochemistry, and mutation analysis of POLE exonuclease domain, should be considered when dealing with a mixed endometrial carcinoma, as these results may provide useful diagnostic insights.
